Results 31 to 40 of about 15,580 (201)

OAT3 Participates in Drug–Drug Interaction between Bentysrepinine and Entecavir through Interactions with M8—A Metabolite of Bentysrepinine—In Rats and Humans In Vitro

Molecules, 2023
Bentysrepinine (Y101) is a novel phenylalanine dipeptide for the treatment of hepatitis B virus. Renal excretion played an important role in the elimination of Y101 and its metabolites, M8 and M9, in healthy Chinese subjects, although the molecular ...
Aijie Zhang, Fanlong Yang, Yang Yuan, Cai Li, Xiaokui Huo, Jing Liu, Shenzhi Zhou, Wei Li, Na Zhang, Jianfeng Liu, Shiqi Dong, Huirong Fan, Ying Peng, Jiang Zheng   +13 more
doaj   +1 more source

Continuous entecavir for treatment-naïve Chinese chronic hepatitis B in the real world setting: the six-year results [PDF]

, 2014
This journal suppl. entitled: 2014 DDW AbstractBACKGROUND: There is a paucity of data on uninterrupted entecavir for treatment-naive chronic hepatitis B (CHB) beyond 5 years.
Fung, J, Ko, MKL, Lai, CL, Lam, YF, Liu, KSH, Mak, LY, Seto, WK, Yuen, RMF   +7 more
core   +1 more source

Evolution of hepatitis B management in kidney transplantation [PDF]

, 2014
published_or_final_versio
Chan, DTM, Yap, YHD
core   +1 more source

Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC)

Viruses, 2021
Hepatitis B virus (HBV) chronic infection causes progressive liver damage, although about 20% of patients develop extrahepatic manifestations such as cryoglobulinemic vasculitis (CV). Clinical manifestations range from mild to moderate (purpura, asthenia,
Cesare Mazzaro, Luigino Dal Maso, Laura Gragnani, Marcella Visentini, Francesco Saccardo, Davide Filippini, Pietro Andreone, Anna Linda Zignego, Valter Gattei, Giuseppe Monti, Massimo Galli, Luca Quartuccio   +11 more
doaj   +1 more source

Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic Hepatitis B virus infected patients [PDF]

, 2012
Natural killer (NK) cells play a critical role in innate antiviral immunity, but little is known about the impact of antiviral therapy on the frequency of NK cell subsets.
Chi, X., Hou, J., Hu, X., Jin, Q., Lv, J., Niu, J., Pan, Y., Sun, H., Tian, Z., Tu, Z., Xiao, W., Xu, D., Yan, H.   +12 more
core   +3 more sources

Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance [PDF]

, 2011
We report a case of an immunocompromised patient affected by chronic hepatitis B virus (HBV) with high basal HBV viremia (>8 log(10) IU/ml) who failed an entecavir regimen, despite the absence of primary or secondary drug resistance mutations.
Andreoni, M, Bertoli, A, Ceccarelli, L, Perno, CF, Salpini, R, Sarrecchia, C, Sordillo, P, Svicher, V, Volpi, A   +8 more
core   +1 more source

Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections [PDF]

, 2021
Background. Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer.
Ahlén, G, Frelin, L, Jagya, N, Johansson, M, Maravelia, P, Meuleman, Philip, Ni, Y, Pasetto, A, Pater, L, Pérez, NC, Sällberg, M, Urban, S, Verch, G, Verhoye, Lieven   +13 more
core   +1 more source

Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma

Gut and Liver, 2016
Background/AimsAntiviral therapy is a key component in the management of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. However, whether the potent drug entecavir is more effective than a less potent drug, such as lamivudine, in
Jung Hee Kim, Dong Hyun Sinn, Kyunga Kim, Hyeseung Kim, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik   +9 more
doaj   +1 more source

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B [PDF]

, 2006
BACKGROUND: Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B.
Chang, TT, Cheinquer, H, Colonno, R, Cross, A, DeHertogh, D, Fernandes, L, Goodman, Z, Lai, CL, Lok, AS, Shouval, D, Wilber, R, Zink, RC   +11 more
core   +1 more source

The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. [PDF]

, 2014
BACKGROUND: To date no network meta-analysis (NMA) has accounted for baseline variations in viral load when assessing the relative efficacy of interventions for chronic hepatitis B (CHB).
A Wiens, ASF Lok, CL Lai, CL Lai, CL Lai, CL Lai, CL Lai, D Caldwell, DC Hoaglin, DJ Lunn, DJ Spiegelhalter, DL Veenstra, DL Veenstra, European Association for the Study of the Liver, F Bonino, F Song, FX Bosch, FY Ren, G Lu, G Salanti, G Woo, G Yao, GK Lau, H Dakin, H Dakin, HL Chan, HL Chan, J Hou, J Shepherd, JL Dienstag, JP Jansen, M Sherman, M Shindo, M Zeng, MH Zheng, N Leung, National Institute for Health and Clinical Excellence, NC Tassopoulos, P Marcellin, P Marcellin, P Marcellin, S Ali, SJ Hadziyannis, SW Schalm, TT Chang, TT Chang, UH Iloeje, WG Cooksley, YF Liaw, YF Liaw, YF Liaw   +50 more
core   +4 more sources